Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021

May 2016 | 148 pages | ID: R47B17D4836EN
iGATE Research Pvt. Ltd.

Abstracts

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. The major driving factors for the renal cell carcinoma drugs market are increasing risk of lifestyle induced diseases, growing prevalence of renal cell carcinoma, increasing geriatric population base and quick diagnosis with modern imaging techniques.

The major drugs used for the treatment of renal cell carcinoma include Sutent, Nexavar, Votrient, Avastin and Inyta amongst others. Sutent accounts for largest share of the global renal cell carcinoma drugs market in 2015, while, Votrient is projected to witness the strongest growth during the forecasting period. The most recent drugs approved for the treatment of renal cell carcinoma is Bristol-Myers Squibb’s Opdivo. Moreover, there are many pipeline drugs in various phases of clinical trials, which will fuel the growth of renal cell carcinoma drugs market.

iGATE RESEARCH report entitled “Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021” provides a comprehensive analysis of the fast-evolving high growth renal cell carcinoma therapeutics market. This 148 Page report with 58 Figures and 4 Tables has been analyzed from 7 viewpoints:

1. Renal Cell Carcinoma (RCC) - Disease Overview
2. Renal Cell Carcinoma (RCC) - Epidemiology
3. Global Renal Cell Carcinoma - Diagnosed Incident Cases to 2023 (8 Countries Covered)
4. Global Renal Cell Carcinoma - Five-Year Diagnosed Prevalent Cases to 2023 (8 Countries Covered)
5. Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)
6. Global Renal Cell Carcinoma Drugs - Pipeline Analysis (18 Drugs Covered)
7. Global Renal Cell Carcinoma Drugs – Market Drivers and Restraints

Global Renal Cell Carcinoma - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases to 2023 (8 Countries Covered)

1. United States
2. Italy
3. Germany
4. France
5. United Kingdom
6. Spain
7. Japan
8. China

Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)

1. Sutent (Sunitinib)
2. Nexavar (Sorafenib)
3. Votrient (Pazopanib)
4. Avastin (Bevacizumab)
5. Afinitor (Everolimus)
6. Inlyta (Axitinib)
7. Torisel (Temsirolimus)
8. Proleukin (Aldesleukin)
9. Opdivo (Nivolumab) - Product Profile
10. Tarceva (Erlotinib) - Product Profile
11. Interferon-alfa - Product Profile

Global Renal Cell Carcinoma Drugs - Pipeline Analysis (17 Companies Drugs Covered)

1. Merck & Co., Inc.
2. Exelixis Inc
3. Argus Therapeutics, Inc.
4. Bristol-Myers Squibb
5. Genentech/Roche
6. Immatics Biotechnologies
7. AVEO Oncology
8. Eisai
9. Acceleron
10. Rexahn Pharmaceuticals
11. Bionomics
12. Cerulean Pharma Inc
13. Celldex Therapeutics
14. TVAX Biomedical
15. TRACON Pharmaceuticals
16. Eli Lilly
17. AstraZeneca

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Contents

1. EXECUTIVE SUMMARY

2. RENAL CELL CARCINOMA (RCC) - DISEASE OVERVIEW

2.1 Etiology and Pathophysiology
  2.1.1 Etiology
  2.1.2 Pathophysiology
2.2 Renal Cell Carcinoma Staging
2.3 Symptoms
2.4 Prognosis
2.5 Potential Biomarkers
  2.5.1 Molecular Markers in Serum
  2.5.2 Molecular Markers in Urine

3. RENAL CELL CARCINOMA (RCC) - EPIDEMIOLOGY

3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Incidence

4. GLOBAL RENAL CELL CARCINOMA - EPIDEMIOLOGICAL FORECAST (2012 - 2023)

4.1 Renal Cell Carcinoma - Global Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
4.2 Renal Cell Carcinoma - Global Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast

5. GLOBAL RENAL CELL CARCINOMA (RCC) - DIAGNOSED INCIDENT CASES AND FIVE-YEAR DIAGNOSED PREVALENT CASES (2012 - 2023)

5.1 United States RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.1.1 RCC - United States Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.1.2 RCC - United States Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast
5.2 Italy RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.2.1 RCC - Italy Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.2.2 RCC - Italy Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast
5.3 Germany RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.3.1 RCC - Germany Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.3.2 RCC - Germany Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast
5.4 France RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.4.1 RCC - France Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.4.2 RCC - France Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast
5.5 United Kingdom RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.5.1 RCC - United Kingdom Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.5.2 RCC - United Kingdom Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast
5.6 Spain RCC- Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.6.1 RCC - Spain Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.6.2 RCC - Spain Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast
5.7 Japan RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.7.1 RCC - Japan Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.7.2 RCC - Japan Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast
5.8 China RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years)
  5.8.1 RCC - China Diagnosed Incident Cases (Ages ≥20 Years) and Forecast
  5.8.2 RCC - China Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast

6. GLOBAL RENAL CELL CARCINOMA - DRUGS MARKET ANALYSIS (2012 - 2021)

6.1 Global Renal Cell Carcinoma - Drugs Market and Forecast
6.2 Global Renal Cell Carcinoma - Drugs Market Share and Forecast

7. GLOBAL RENAL CELL CARCINOMA - MAJOR BRANDED DRUGS PRODUCT PROFILES AND SALES

7.1 Sutent (Sunitinib) - Product Profile and Sales
  7.1.1 Sutent (Sunitinib) - Product Profile
  7.1.2 Sutent (Sunitinib) - Global Sales and Forecast (2012 - 2021)
7.2 Nexavar (Sorafenib) - Product Profile and Sales
  7.2.1 Nexavar (Sorafenib) - Product Profile
  7.2.2 Nexavar (Sorafenib) - Global Sales and Forecast (2012 - 2021)
7.3 Votrient (Pazopanib) - Product Profile and Sales
  7.3.1 Votrient (Pazopanib) - Product Profile
  7.3.2 Votrient (Pazopanib) - Global Sales and Forecast (2012 - 2021)
7.4 Avastin (Bevacizumab) - Product Profile and Sales
  7.4.1 Avastin (Bevacizumab) - Product Profile
  7.4.2 Avastin (Bevacizumab) - Global Sales and Forecast (2012 - 2021)
7.5 Afinitor (Everolimus) - Product Profile and Sales
  7.5.1 Afinitor (Everolimus) - Product Profile
  7.5.2 Afinitor (Everolimus) - Global Sales and Forecast (2012 - 2021)
7.6 Inlyta (Axitinib) - Product Profile and Sales
  7.6.1 Inlyta (Axitinib) - Product Profile
  7.6.2 Inlyta (Axitinib) - Global Sales and Forecast (2012 - 2021)
7.7 Torisel (Temsirolimus) - Product Profile and Sales
  7.7.1 Torisel (Temsirolimus) - Product Profile
  7.7.2 Torisel (Temsirolimus) - Global Sales and Forecast (2012 - 2021)
7.8 Proleukin (Aldesleukin) - Product Profile and Sales
  7.8.1 Proleukin (Aldesleukin) - Product Profile
  7.8.2 Proleukin (Aldesleukin) - Global Sales and Forecast (2012 - 2021)
7.9 Opdivo (Nivolumab) - Product Profile
7.10 Tarceva (Erlotinib) - Product Profile
7.11 Interferon-alfa - Product Profile

8. GLOBAL RENAL CELL CARCINOMA DRUGS MARKET – COMPANY WISE PIPELINE ANALYSIS

8.1 Merck & Co., Inc.
8.2 Merck & Co., Inc.
8.3 Exelixis Inc
8.4 Argus Therapeutics, Inc.
8.5 Bristol-Myers Squibb
8.6 Genentech/Roche
8.7 Immatics Biotechnologies
8.8 AVEO Oncology
8.9 Eisai
8.10 Acceleron
8.11 Rexahn Pharmaceuticals
8.12 Bionomics
8.13 Cerulean Pharma Inc.
8.14 Celldex Therapeutics
8.15 TVAX Biomedical
8.16 TRACON Pharmaceuticals
8.17 Eli Lilly
8.18 AstraZeneca

9. GLOBAL RENAL CELL CARCINOMA DRUGS - MARKET DRIVERS

9.1 Rising Incidence of Renal Cell Carcinoma Expected to Fuel Market Growth
9.2 Increasing Elderly Population Likely to Drive Renal Cell Carcinoma Drugs Market
9.3 Strong Pipeline Candidates is Expected to Drive Market Growth
9.4 Novel Treatment Option for Renal Cell Carcinoma

10. GLOBAL RENAL CELL CARCINOMA DRUGS - MARKET RESTRAINTS

10.1 High Prices of Branded Renal Cell Carcinoma Drugs
10.2 Increasing Preference for Generic Drug Variants Would Hamper the Market

List Of Figures

LIST OF FIGURES:

Figure 4-1: Global - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 4-2: Global - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 4-3: Global - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 4-4: Global - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-1: United States - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-2: United States - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-3: United States - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-4: United States - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-5: Italy - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-6: Italy - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-7: Italy - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-8: Italy - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-9: Germany - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-10: Germany - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-11: Germany - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-12: Germany - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-13: France - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-14: France - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-15: France - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-16: France - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-17: United Kingdom - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-18: United Kingdom - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-19: United Kingdom - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-20: United Kingdom - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-21: Spain - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-22: Spain - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-23: Spain - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-24: Spain - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-25: Japan - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-26: Japan - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-27: Japan - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-28: Japan - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-29: China - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-30: China - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 5-31: China - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015
Figure 5-32: China - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023
Figure 6-1: Global - Renal Cell Carcinoma Drugs Market (Million US$), 2012 - 2015
Figure 6-2: Global - Forecast for Renal Cell Carcinoma Drugs Market (Million US$), 2016 - 2021
Figure 6-3: Global - Renal Cell Carcinoma Drugs Market Share (Percent), 2012 - 2015
Figure 6-4: Global - Forecast for Renal Cell Carcinoma Drugs Market Share (Percent), 2016 - 2021
Figure 7-1: Sutent (Sunitinib) - Global Sales (Million US$), 2012 - 2015
Figure 7-2: Sutent (Sunitinib) - Forecast for Global Sales (Million US$), 2016 - 20121
Figure 7-3: Nexavar (Sorafenib) - Global Sales (Million US$), 2012 - 2015
Figure 7-4: Nexavar (Sorafenib) - Forecast for Global Sales (Million US$), 2016 - 2021
Figure 7-5: Votrient (Pazopanib) - Global Sales (Million US$), 2012 - 2015
Figure 7-6: Votrient (Pazopanib) - Forecast for Global Sales (Million US$), 2016 - 2021
Figure 7-7: Avastin (Bevacizumab) - Global Sales (Million US$), 2012 - 2015
Figure 7-8: Avastin (Bevacizumab) - Forecast for Global Sales (Million US$), 2016 - 2021
Figure 7-9: Afinitor (Everolimus) - Global Sales (Million US$), 2012 - 2015
Figure 7-10: Afinitor (Everolimus) - Forecast for Global Sales (Million US$), 2016 - 2021
Figure 7-11: Inlyta (Axitinib) - Global Sales (Million US$), 2012 - 2015
Figure 7-12: Inlyta (Axitinib) - Forecast for Global Sales (Million US$), 2016 - 2021
Figure 7-13: Torisel (Temsirolimus) - Global Sales (Million US$), 2012 - 2015
Figure 7-14: Torisel (Temsirolimus) - Forecast for Global Sales (Million US$), 2016 - 2021
Figure 7-15: Proleukin (Aldesleukin) - Global Sales (Million US$), 2012 - 2015
Figure 7-16: Proleukin (Aldesleukin) - Forecast for Global Sales (Million US$), 2016 - 2021
Figure 9-1: World Population - Over 60 Years of Age (Thousand), 2012 - 2015
Figure 9-2: World Population - Forecast for Over 60 Years of Age (Thousand), 2016 - 2021

List Of Tables

LIST OF TABLES:

Table 2-1: Percentage of People Surviving the Cancer (Percent)
Table 2-2: Potential Serum Biomarkers in Renal Cell Carcinoma
Table 2-3: Potential Urinary Biomarkers in Renal Cell Carcinoma
Table 9-1: Renal Cell Carcinoma - List of Drugs in the Pipeline (February 2016)